• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Aripiprazole Augmentation May Improve Remission Rates in MDD

Aripiprazole Augmentation May Improve Remission Rates in MDD

November 1, 2017
Ricardo Arechiga, PharmD candidate (2018)
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Ricardo Arechiga, PharmD candidate (2018) Mr. Arechiga has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Mohamed S et al, JAMA 2017;318(2):132–145

It seems like an endless debate: When a patient does not respond to the first trial of an antidepressant, what should we do? Switch to something else? Augment with another agent? If the latter, how often should that augmenting agent be an atypical antipsychotic? The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial was conducted to answer some of these questions. Specifically, the study compared the effectiveness and adverse effects of switching to bupropion SR, augmenting with bupropion SR, or augmenting with aripiprazole.

In this randomized controlled trial, 1,522 patients with non-psychotic major depressive disorder (MDD) who had failed at least one adequate 6-week course of an SSRI, an SNRI, or mirtazapine were recruited from the Veterans’ Administration (VA). Most of the patients were male (85%) and white (69%), and had an average age of 54.4. Patients were randomly assigned to one of three groups: switching to bupropion (most common dose 200 mg twice daily, n = 511), augmenting with bupropion (most common dose also 200 mg twice daily, n = 506), or augmenting with aripiprazole (most common dose 10 mg daily, n = 505). After 12 weeks of treatment, remission and response rates were: switch-bupropion: remission 22%, response 62%; augment-bupropion: remission 27%, response 66%; augment-aripiprazole: remission 29%, response 74%. Augmenting with aripiprazole yielded statistically superior remission rates than switching to bupropion (P = .02) and superior response rates than either of the bupropion arms. Somnolence, akathisia, and weight gain occurred more frequently in the aripiprazole group. Most dramatically, in a subset of patients who continued the trial for 36 weeks, 25% of the aripiprazole group gained at least 7% of body weight as opposed to only 5% of both bupropion groups.

TCPR’s Take
Aripiprazole augmentation was the most effective strategy for patients who had not responded to a single antidepressant trial, beating both switching to and augmenting with bupropion. While aripiprazole’s superiority was not huge, it was clinically significant, with a number needed to treat (NNT) of around 10 when compared with switching to bupropion. But the price of this higher response rate is a cluster of side effects, including weight gain, akathisia, and somnolence. In addition, these results may not generalize to non-VA populations, such as women of any age and younger men. Nonetheless, this large and well-designed study should encourage us to consider aripiprazole augmentation as a solid second-step strategy in depression treatment.
General Psychiatry
KEYWORDS antidepressants research_updates
    Ricardo Arechiga, PharmD candidate (2018)

    Can Strattera Improve Reading Skills in Children With Dyslexia?

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Closing a Practice: Some Practical Suggestions
    Financial Planning for Retirement
    Aripiprazole Augmentation May Improve Remission Rates in MDD
    Fluoxetine Plus CBT for Somatic Symptom Disorder
    CME Post-Test - Retirement, TCPR, November 2017
    Note From the Editor-in-Chief
    Retirement Toolkits
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.